Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Torii Pharmaceutical Co Ltd
4551Torii Pharmaceutical Co., Ltd. manufactures and markets pharmaceutical products in Japan. It offers therapeutic agents, such as Riona for the treatment of hyperphosphatemia; and REMITCH, an oral therapeutic agent for the treatment of pruritus in dialysis and liver disease patients. The company also provides ANTEBATE that is used for the treatment of skin diseases, such as atopic dermatitis and contact dermatitis by reducing inflammation; CORECTIM, a topical janus kinase (JAK) inhibitor; and allergen immunotherapy tablets comprising CEDARCURE and MITICURE. In addition, it is engaged in real estate rental business. The company markets its products primarily through medical representatives for medical professionals. The company has a collaboaration with ALK-Abelló A/S to develop, market and distribute ALK's allergy immunotherapy tablet for the treatment of grass pollen allergy. The company was formerly known as Torii Shoten K.K and changed its name to Torii Pharmaceutical Co., Ltd. in May 1949. The company was founded in 1872 and is headquartered in Tokyo, Japan. Torii Pharmaceutical Co., Ltd. is a subsidiary of Japan Tobacco Inc. Address: Torii Nihonbashi Bldg., Tokyo, Japan, 103-8439
Analytics
Preço Alvo de Wall Street
626 962.84 JPYRácio P/E
24.0543Rendimento de dividendos
2.84 %Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave 4551
Análise de Dividendos 4551
Crescimento de dividendos em 5 anos
150 %Crescimento contínuo
2 anosTaxa de pagamento em média de 5 anos
49 %Histórico de Dividendos 4551
Avaliação de ações 4551
Relatório 4551
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |